Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Areya Tabatabai

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Molecular Cancer Therapeutics|March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer ModelRhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Frontiers in Immunology|December 21, 2023
Mouse models of diffuse large B cell lymphomaAreya Tabatabai, Aastha Arora, Svenja Höfmann, et al.
Nature Communications|April 23, 2021
Proteomics of protein trafficking by in vivo tissue-specific labelingIlia A Droujinine, Amanda S Meyer, Dan Wang, et al.
Blood Advances|December 7, 2023
An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphomaRuth Flümann, Julia Hansen, Jörn Meinel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Molecular Cancer Therapeutics|March 8, 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer ModelRhys D O Jones, Klas Petersson, Areya Tabatabai, et al.
Frontiers in Immunology|December 21, 2023
Mouse models of diffuse large B cell lymphomaAreya Tabatabai, Aastha Arora, Svenja Höfmann, et al.
Nature Communications|April 23, 2021
Proteomics of protein trafficking by in vivo tissue-specific labelingIlia A Droujinine, Amanda S Meyer, Dan Wang, et al.
Blood Advances|December 7, 2023
An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphomaRuth Flümann, Julia Hansen, Jörn Meinel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting ThrombocytopeniaSrividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Pageof 1